RXi Pharmaceuticals (RXi) continues to make solid progress with its development pipeline. We anticipate one of two promising cosmeceutical candidates to enter human testing this year, moving forward on an expedited pathway for potential launch in 2019. We also expect data in H216 in all lead projects including RXI-109 in dermal scarring and in retinal scarring in wet AMD, and Samcyprone in cutaneous warts.
